J Pathol Transl Med.  2019 Sep;53(5):273-279. 10.4132/jptm.2019.05.12.

Human Papillomavirus Serologic Profiles of Selected Filipinos with Head and Neck Squamous Cell Carcinoma

• Albano PM
• Salvador C
• Orosa J
• Racelis S
• Leaño M
• Michel A
• Ramos JD
• Holzinger
• Pawlita M

• KMID: 2459575
• DOI: http://doi.org/10.4132/jptm.2019.05.12

Abstract

BACKGROUND
The low prevalence of human papillomavirus (HPV) DNA and mRNA in biopsy samples of Filipinos with head and neck squamous cell carcinoma (HNSCC) has been reported previously. Here, the HPV serologic profiles of HNSCC cases were analyzed and associated with lifestyle and sexual practices.
METHODS
Serum samples were collected between May 2012 and September 2013 from HNSCC patients (n = 22) in the northwest region of the Philippines, and age- and sex-matched clinically healthy controls. Antibodies to capsid and early oncoproteins of HPV16, 18, 31, 33, 45, 52, 58, 6, and 11 were analyzed using multiplex serology.
RESULTS
Most of the cases were males with tumors of the oral cavity or larynx. Two of the cases tested positive for at least one of the early oncoproteins (E6, E7, E1, and/or E2) of HPV16, and 11 did not display reactivity to any HPV early or late oncoproteins. Of the controls, four tested positive for at least one of the HPV16 early oncoproteins, and 10 were non-reactive to all HPV types. Titers to HPV16 E6 or E7 of the seropositive cases and controls were considerably lower than those typically observed in economically developed countries.
CONCLUSIONS
The low HPV titers seen here are consistent with the results of molecular analyses for this population. Hence, the seropositivity of some of the HNSCC cases is likely an indication of prior exposure to the virus and not the presence of HPV-driven tumors.

Keyword

HPV antibodies; Head and neck squamous cell carcinoma; Philippines; Multiplex serology

MeSH Terms

Antibodies
Biopsy
Capsid
Carcinoma, Squamous Cell*
Developed Countries
DNA
Epithelial Cells*
Head*
Humans*
Larynx
Life Style
Male
Mouth
Neck*
Oncogene Proteins
Philippines
Prevalence
RNA, Messenger
Antibodies
DNA
Oncogene Proteins
RNA, Messenger

Reference

1. Monie A, Hung CF, Roden R, Wu TC. Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics. 2008; 2:97–105.

2. D’Souza G, Dempsey A. The role of HPV in head and neck cancer and review of the HPV vaccine. Prev Med. 2011; 53 Suppl 1:S5–11.

3. D’Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007; 356:1944–56.

4. Kreimer AR, Pierce Campbell CM, Lin HY, et al. Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study. Lancet. 2013; 382:877–87.

5. Ribeiro KB, Levi JE, Pawlita M, et al. Low human papillomavirus prevalence in head and neck cancer: results from two large case-control studies in high-incidence regions. Int J Epidemiol. 2011; 40:489–502.

6. Wyss A, Hashibe M, Chuang SC, et al. Cigarette, cigar, and pipe smoking and the risk of head and neck cancers: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Am J Epidemiol. 2013; 178:679–90.

7. Herrero R, Castellsagué X, Pawlita M, et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst. 2003; 95:1772–83.

8. Michaud DS, Langevin SM, Eliot M, et al. High-risk HPV types and head and neck cancer. Int J Cancer. 2014; 135:1653–61.

9. Lang Kuhs KA, Pawlita M, Gibson SP, et al. Characterization of human papillomavirus antibodies in individuals with head and neck cancer. Cancer Epidemiol. 2016; 42:46–52.

10. Kreimer AR, Johansson M, Waterboer T, et al. Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol. 2013; 31:2708–15.

11. Anderson KS, Wong J, D'Souza G, et al. Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer. Br J Cancer. 2011; 104:1896–905.

12. Rubenstein LM, Smith EM, Pawlita M, Haugen TH, Hamšíková E, Turek LP. Human papillomavirus serologic follow-up response and relationship to survival in head and neck cancer: a case-comparison study. Infect Agent Cancer. 2011; 6:9.

13. Smith EM, Pawlita M, Rubenstein LM, Haugen TH, Hamsikova E, Turek LP. Risk factors and survival by HPV-16 E6 and E7 antibody status in human papillomavirus positive head and neck cancer. Int J Cancer. 2010; 127:111–7.

14. Smith EM, Ritchie JM, Pawlita M, et al. Human papillomavirus seropositivity and risks of head and neck cancer. Int J Cancer. 2007; 120:825–32.

15. Albano PM, Holzinger D, Salvador C, et al. Low prevalence of human papillomavirus in head and neck squamous cell carcinoma in the northwest region of the Philippines. PLoS One. 2017; 12:e0172240.

16. Waterboer T, Sehr P, Pawlita M. Suppression of non-specific binding in serological Luminex assays. J Immunol Methods. 2006; 309:200–4.

17. Waterboer T, Sehr P, Michael KM, et al. Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin Chem. 2005; 51:1845–53.

18. Clifford GM, Shin HR, Oh JK, et al. Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea. Cancer Epidemiol Biomarkers Prev. 2007; 16:1874–9.

19. Anantharaman D, Gheit T, Waterboer T, et al. Human papillomavirus infections and upper aero-digestive tract cancers: the ARCAGE study. J Natl Cancer Inst. 2013; 105:536–45.

20. Egawa N, Doorbar J. The low-risk papillomaviruses. Virus Res. 2017; 231:119–27.

21. Baboci L, Boscolo-Rizzo P, Holzinger D, et al. Evidence of the causal role of human papillomavirus type 58 in an oropharyngeal carcinoma. Virol J. 2013; 10:334.

22. Boscolo-Rizzo P, Pawlita M, Holzinger D. From HPV-positive towards HPV-driven oropharyngeal squamous cell carcinomas. Cancer Treat Rev. 2016; 42:24–9.

23. Broglie MA, Jochum W, Michel A, et al. Evaluation of type-specific antibodies to high risk-human papillomavirus (HPV) proteins in patients with oropharyngeal cancer. Oral Oncol. 2017; 70:43–50.

24. Lajer CB, von Buchwald C. The role of human papillomavirus in head and neck cancer. APMIS. 2010; 118:510–9.

25. Smith EM, Ritchie JM, Summersgill KF, et al. Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int J Cancer. 2004; 108:766–72.

26. Chaturvedi AK. Epidemiology and clinical aspects of HPV in head and neck cancers. Head Neck Pathol. 2012; 6 Suppl 1:S16–24.